Intervention: Regorafenib
Trial phase: Phase 2
ATC code: L01EX05 | L01XE21
SMILES: CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: 120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)

Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast.

Regorafenib: Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed colorectal adenocarcinoma
Measurable metastatic disease.
Age +/> 70
Progression on standard therapy, not a candidate for further chemotherapy or patient declines other options
Life expectancy >/= 12 weeks
Able to understand and willing to sign written informed consent.
Laboratory requirements:
Total bili ≤ 1.5 x upper limit or normal
Alanine aminotransferase & Asparate aminotransferase ≤ 2.5 x upper limit or normal
Serum creatinine ≤ 1.5 x upper limit or normal
International normalized ratio/prothrombin time ≤ 1.5 x upper limit or normal
Platelet count ≥ 100,000, hemoglobin ≥ 9 g/dL
Absolute neutrophil count ≥ 1,500. Blood transfusion to meet the inclusion criteria not be allowed.
Glomerular filtration rate ≥ 60 ml/min
Subjects of childbearing potential must agree to use adequate contraception beginning at the signing informed consent form until at least 3 months after the last dose of study drug.
Must be able to swallow and retain oral medications

Exclusion Criteria:

Currently receiving other systemic therapy for metastatic colorectal cancer
Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.
Uncontrolled hypertension despite optimal medical management
Active or clinically significant cardiac disease.
Evidence or history of bleeding diathesis or coagulopathy
Any hemorrhage or bleeding event ≥ grade 3 within 4 weeks.
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within 6 months of informed consent
History of other active malignancy within past 2 years.
Patients with phaeochromocytoma
Known history of human immunodeficiency virus infection or current chronic/active hepatitis B or C infection.
Ongoing infection > grade 2
Symptomatic metastatic brain or meningeal tumors
Presence of non-healing wound, non-healing ulcer, or bone fracture
Renal failure requiring hemo- or peritoneal dialysis
Dehydration ≥ grade 1
Patients with seizure disorder requiring medication
Persistent proteinuria ≥ grade 3 Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea
History of organ allograft including corneal transplant
Known or suspected allergy or hypersensitivity to the study drug
Any malabsorption condition
Any condition which makes the subject unsuitable for trial participation
Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study.